GlassScriptPhysician profile
Maria C Bellmann
NPI 1902832629
$2,669.82
in general payments reported to CMS, 2019-2025
27 companies · $505 in 2025
The $505 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $299 · 2021: $326 · 2022: $87.44 · 2023: $481 · 2024: $452 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.94 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.71 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $327.74 | 2020-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $247.85 | 2019-2023 | Balcoltra |
| Astellas Pharma US INC | $226.06 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $173.68 | 2019-2023 | Mara Console |
| Myriad Women'S Health, INC. | $134.98 | 2023 | Myrisk |
| Lupin INC. | $128.46 | 2019-2020 | |
| Sage Therapeutics, LLC | $123.65 | 2024-2025 | Zurzuvae |
| Millicent US INC | $98.51 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $75.98 | 2024-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $74.05 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $72.85 | 2019-2021 | |
| Organon LLC | $67.20 | 2022-2025 | Jada System |
| Exeltis, USA INC. | $64.41 | 2023-2025 | Slynd |
| Mayne Pharma Commercial LLC | $49.49 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $49.03 | 2024 | |
| Novo Nordisk INC | $42.48 | 2023-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $35.86 | 2021-2023 | |
| Hologic Sales and Service, LLC | $33.27 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $25.68 | 2025 | Qelbree |
| Medtronic, INC. | $24.38 | 2025 | Ligasure |
| Dexcom, INC. | $22.81 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $19.74 | 2019 | |
| Duchesnay USA Incorporated | $14.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.68 | 2019 | |
| Amgen INC. | $14.21 | 2023 | Evenity, Prolia |
| Currax Pharmaceuticals LLC | $13.14 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Bellmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.